A couple has filed a new Eliquis lawsuit, alleging that the blood thinning medication prescribed to treat the wife’s atrial fibrillation has put her in danger with internal bleeding complications. Eliquis is made by Pfizer and Bristol-Myers Squibb and is designed to reduce the overall risk of blood clot injuries.
The plaintiffs have alleged that Pfizer and Bristol-Myers Squib neglected to warn of the potentially adverse effects of Eliquis. When the plaintiff who suffers from atrial fibrillation condition consulted with her physician about her treatment options, she chose Eliquis on the basis of the marketing materials that were presented by the pharmaceutical companies.
Eliquis was approved by the U.S. Food and Drug Administration (FDA) in 2012 and released as a joint effort between Pfizer and Bristol-Myers Squibb. Eliquis is the third in a series of new generation anticoagulants made to compete against the established blood thinner Warfain (coumadin).
These blood thinning drugs work by inhibiting the body’s clotting mechanism, and to provide a smooth blood flow. The down side is that the body is then hampered in its ability to recover from internal bleeding injuries, that may require medical intervention to save the patient’s life. Currently, Warfarin is the only blood thinner with an available bleeding antidote in case of an emergency internal bleeding event.
Warfarin requires rigorous monitoring with relatively strict dietary guidelines and regular dosage adjustments, so the new generation anticoagulants were praised as more convenient, but lacked the precautions the original blood thinner required. The lawsuit alleges that the manufacturing companies failed to mention the risk of highly dangerous complications on their respective medications’ labels.
The plaintiff in the Eliquis lawsuit had always followed prescription instructions but still experienced uncontrollable internal bleeding, which had required emergency treatment. The plaintiff stated that she would never have taken Eliquis if she had been aware of the uncontrollable internal bleeding risks.